Aravive to Participate in Upcoming Virtual Investor Conferences in March

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company, announced its participation in two virtual investor conferences in March 2021. The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, with Aravive's presentation available for viewing on March 9. The Oppenheimer 31st Annual Healthcare Conference is scheduled for March 18 at 8:00 a.m. ET. Archived presentations will be accessible for 90 days. Aravive is advancing its lead product candidate, AVB-500, which targets tumor growth pathways and has shown promising results in trials for ovarian and renal cancer.

HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in March:

• H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. Aravive’s presentation will be available for viewing on March 9, 2021.
• Oppenheimer 31^st Annual Healthcare Conference on Thursday, March 18, 2021, at 8:00 a.m. ET

Live webcasts and audio archives of the presentations will be available at http://ir.aravive.com. Archived replays of the webcasts will be available for 90 days following the presentations.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Aravive’s lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and plans to initiate a pivotal Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company has initiated and is recruiting for its Phase 1b/2 trial in patients with clear cell renal cell carcinoma.

Contacts:
Media:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
(949) 903-4750

Investors:
Luke Heagle, W2O
lheagle@w2ogroup.com
(910) 726-1372

FAQ

What conferences will Aravive (ARAV) participate in March 2021?

Aravive will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10 and the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021.

When will Aravive's presentation be available for viewing?

Aravive's presentation at the H.C. Wainwright Global Life Sciences Conference will be available for viewing on March 9, 2021.

How can I access Aravive's conference presentations?

Live webcasts and audio archives of Aravive's presentations will be available at their investor relations website, with replays accessible for 90 days after the events.

What is AVB-500 and its significance for Aravive?

AVB-500 is Aravive's lead product candidate designed to target the GAS6-AXL signaling pathway, showing clinical benefit in trials for platinum-resistant ovarian cancer and ongoing studies in renal cell carcinoma.

What were the results of the Phase 1b trial for AVB-500?

In the Phase 1b trial for AVB-500, all 5 patients in the 15 mg/kg cohort experienced clinical benefit: 1 complete response, 2 partial responses, and 2 stable disease outcomes.